Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AssigneeGenomic Health, Inc.
InventorsWayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
Life of this patent
Estimating the term…
Abstract
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Claims20
A method of analyzing the expression of RNA transcripts of genes in a human renal cancer patient, the method comprising:
- measuring levels of RNA transcripts, in a renal tumor sample from the patient, of a panel of genes consisting of:
- a set of genes consisting of one or more angiogenesis genes selected from:
- ADD1, ANGPTL3, APOLD1, CEACAM1, EDNRB, EMCN, ENG, EPAS1, FLT1, JAG1, KDR, KL, LDB2, NOS3, NUDT6, PPAP2B, PRKCH, PTPRB, RGS5, SHANK3, SNRK, TEK, ICAM2, and VCAM1;
- a set of genes consisting of one or more immune response genes selected from:
- CCL5, CCR7, CD8A, CX3CL1, CXCL10, CXCL9, HLA-DPB1, IL6, IL8, and SPP1;
- and
- a set of genes consisting of one or more cell cycle genes selected from:
- BUB1, C13orf15, CCNB1, PTTG1, TPX2, LMNB1, and TUBB2A;
- EIF4EBP1;
- and
- a set of genes consisting of one or more reference genes.
A method of analyzing the expression of RNA transcripts of genes in a human renal cancer patient, the method comprising:
- measuring levels of RNA transcripts, in a renal tumor sample from the patient, of a panel of genes consisting of:
- a set of genes consisting of one or more angiogenesis genes selected from:
- ADD1, ANGPTL3, APOLD1, CEACAM1, EDNRB, EMCN, ENG, EPAS1, FLT1, JAG1, KDR, KL, LDB2, NOS3, NUDT6, PPAP2B, PRKCH, PTPRB, RGS5, SHANK3, SNRK, TEK, ICAM2, and VCAM1;
- a set of genes consisting of one or more immune response genes selected from:
- CCL5, CCR7, CD8A, CX3CL1, CXCL10, CXCL9, HLA-DPB1, IL6, IL8, and SPP1;
- and
- a set of genes consisting of one or more cell cycle genes selected from:
- BUB1, C13orf15, CCNB1, PTTG1, TPX2, LMNB1, and TUBB2A;
- a set of genes consisting of one or more transport genes selected from:
- AQP1, SGK1, and both AQP1 and SGK1;
- a set of genes consisting of one or more cell adhesion/extracellular matrix genes selected from:
- ITGB1, A2M, ITGB5, LAMB1, LOX, MMP14, TGFBR2, TIMP3, and TSPAN7;
- EIF4EBP1;
- and
- a set of genes consisting of one or more reference genes.
A method of analyzing the expression of RNA transcripts of genes in a human renal cancer patient, the method comprising:
- measuring levels of RNA transcripts, in a renal tumor sample from the patient, of a panel of genes consisting of:
- (a) at least five genes selected from the group consisting of:
- EMCN, PPAP2B, CCL5, CXCL9, NOS3, NUDT6, AQP1, APOLD1, ITGB5, CCR7, CX3CL1, CEACAM1, PRKCH, CASP10, SNRK, and PTPRB, and
- (b) a set of genes consisting of one or more reference genes.
Dependencies are inferred from the claim text.